Friday, May 1, 2026

Shocking Verdict: Doctors Sentenced for Late-Term Abortion in South Korea

Doctors sentenced for performing an illegal abortion on a 36-week pregnant woman, who received a suspended sentence due to lack of support.

BYD’s Partnership with DeepSeek Sparks Data Privacy Fears in Korea

BYD's partnership with DeepSeek raises data security concerns in Korea, potentially impacting sales of its autonomous vehicles.

400+ WARHEADS By 2040: North Korea Shifts Strategy To Annihilate The Nuclear Status Quo

North Korea's nuclear arsenal may exceed 400 weapons by 2040, bolstered by military ties with Russia and a shift in strategy.

Jung Eun Kim

Author's Latest

Cancer Gone for 3 Years? This New Drug Is Making It Happen

AbbVie's Epkinly shows 96% long-term complete remission in R/R large B-cell lymphoma patients, highlighting its effectiveness as a therapy.

J&J Aims to Treat Cancer Before It Starts Showing Symptoms

Johnson & Johnson leads in multiple myeloma treatment, pioneering early intervention for high-risk patients with a new subcutaneous formulation.

Opdivo Wins EU Approval in Big Step for Early Lung Cancer Treatment

Opdivo gains EU approval for perioperative therapy in NSCLC, enhancing competition with Keytruda and marking a treatment paradigm shift.

Ozempic Maker Swaps CEO, Bets $2.2B on New Obesity Drug Fight

Novo Nordisk's leadership change aims to reclaim its obesity treatment market share amid competition from Eli Lilly's Mounjaro.

New Study: Mounjaro Helps Users Drop Over 50 Pounds

Eli Lilly's Mounjaro leads U.S. obesity drug market, outperforming semaglutide in weight loss efficacy and safety.

Novo Nordisk and Lilly Block Generics, Tighten Grip on $125B GLP-1 Market

Novo Nordisk and Eli Lilly secure court victories against generics, maintaining dominance in the GLP-1 treatment market amid rising demand.

Novo Nordisk Pushes for First Oral Obesity Drug Approval

Novo Nordisk seeks FDA approval for oral Wegovy, potentially the first oral obesity treatment, amid competition with Eli Lilly.

Eli Lilly’s Oral GLP-1 Shows 7.9% Weight Loss in Type 2 Diabetes Trial

Eli Lilly's orforglipron shows promise in Phase 3 trials for diabetes and obesity, offering an oral alternative to injectables.

President Yoon Announces Historic Oil Discovery in South Korea

After President Yoon announced the "potential for a massive amount of oil and natural gas reserves off Pohang," oil stocks have risen.

Top News

- Our Sponsors Ad -

Follow us

Cars

Tech

future

health

© Copyright by News1. All Rights Reserved.